Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
743 participants
OBSERVATIONAL
2009-10-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension
NCT03847350
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
NCT06130124
Effect of Different Antihypertensive Drugs on Central Blood Pressure
NCT05328310
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
NCT01415531
Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean ISH Patients Aged 60 to 80 Years
NCT00460915
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Nebivolol will be administered to Hypertension or Chronic heart failure (CHF) patients as described the prescribing information of Nebivolol by physician's decision.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients administrated Nebivolol
There is only one group. This group includes patients administrated Nebivolol
Nebivolol
patients administrated Nebivolol according to the prescribing information
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nebivolol
patients administrated Nebivolol according to the prescribing information
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with indication in the prescribing information
* Subjects administrated Nebivolol by physician's decision
* Subjects with no contraindication according to the prescribing information
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
113554
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.